Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AYTU NASDAQ:HRTX NYSE:JATT NASDAQ:RLYB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYTUAytu BioPharma$2.16$2.19$1.65▼$3.07$23.18M0.2420,948 shs10,409 shsHRTXHeron Therapeutics$0.46-0.7%$0.53$0.38▼$1.93$86.88M1.652.84 million shs1.16 million shsJATTJATT Acquisition$11.31+3.7%$10.91$9.99▼$12.63$90.76MN/A20,484 shs17,630 shsRLYBRallybio$16.31-0.5%$15.79$3.20▼$17.57$86.84M-0.944,309 shs41,589 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYTUAytu BioPharma0.00%+0.47%-1.37%-14.29%-17.87%HRTXHeron Therapeutics-0.70%-3.17%+4.78%-61.70%-76.74%JATTJATT Acquisition-8.24%+1.03%+8.44%+5.94%+573.21%RLYBRallybio-0.49%-0.67%+2.45%+88.99%+285.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYTUAytu BioPharma$2.16$2.19$1.65▼$3.07$23.18M0.2420,948 shs10,409 shsHRTXHeron Therapeutics$0.46-0.7%$0.53$0.38▼$1.93$86.88M1.652.84 million shs1.16 million shsJATTJATT Acquisition$11.31+3.7%$10.91$9.99▼$12.63$90.76MN/A20,484 shs17,630 shsRLYBRallybio$16.31-0.5%$15.79$3.20▼$17.57$86.84M-0.944,309 shs41,589 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYTUAytu BioPharma0.00%+0.47%-1.37%-14.29%-17.87%HRTXHeron Therapeutics-0.70%-3.17%+4.78%-61.70%-76.74%JATTJATT Acquisition-8.24%+1.03%+8.44%+5.94%+573.21%RLYBRallybio-0.49%-0.67%+2.45%+88.99%+285.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAYTUAytu BioPharma 2.00Hold$10.75397.69% UpsideHRTXHeron Therapeutics 2.00Hold$2.50448.49% UpsideJATTJATT Acquisition 0.00N/AN/AN/ARLYBRallybio 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest AYTU, HRTX, JATT, and RLYB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026HRTXHeron Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/15/2026AYTUAytu BioPharma Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell7/6/2026AYTUAytu BioPharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/11/2026AYTUAytu BioPharma Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $14.506/3/2026HRTXHeron Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$2.006/2/2026HRTXHeron Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold5/11/2026HRTXHeron Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/11/2026AYTUAytu BioPharma Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/8/2026RLYBRallybio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/27/2026HRTXHeron Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAYTUAytu BioPharma$66.38M0.35$0.38 per share5.75$2.11 per share1.02HRTXHeron Therapeutics$154.90M0.56N/AN/A$0.07 per share6.51JATTJATT AcquisitionN/AN/A$0.42 per share27.08($0.53) per shareN/ARLYBRallybio$860K100.52N/AN/A$10.98 per share1.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAYTUAytu BioPharma-$13.56M-$4.58N/A8.64N/A-60.17%-69.93%-13.25%9/29/2026 (Estimated)HRTXHeron Therapeutics-$20.19M-$0.18N/AN/AN/A-20.53%-7,747.30%-8.94%8/14/2026 (Estimated)JATTJATT Acquisition$6.85MN/AN/AN/AN/AN/A-49.58%2.84%N/ARLYBRallybio-$8.98M-$4.34N/AN/AN/A-911.07%-55.79%-51.48%8/6/2026 (Estimated)Latest AYTU, HRTX, JATT, and RLYB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2026Q2 2026HRTXHeron Therapeutics-$0.02N/AN/AN/A$42.19 millionN/A8/6/2026N/ARLYBRallybio-$1.28N/AN/AN/A$0.22 millionN/A5/13/2026Q3 2026AYTUAytu BioPharma-$0.4433-$0.53-$0.0867-$0.53$12.05 million$12.41 million5/13/2026Q1 2026RLYBRallybio-$1.20-$1.46-$0.26-$1.46$0.21 million$0.21 million5/11/2026Q1 2026HRTXHeron Therapeutics-$0.03-$0.04-$0.01-$0.04$36.72 million$34.71 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAYTUAytu BioPharmaN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/ARLYBRallybioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAYTUAytu BioPharma0.271.121.00HRTXHeron Therapeutics17.512.531.51JATTJATT AcquisitionN/A0.150.15RLYBRallybioN/A12.9212.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAYTUAytu BioPharma33.49%HRTXHeron Therapeutics80.01%JATTJATT Acquisition47.97%RLYBRallybio90.34%Insider OwnershipCompanyInsider OwnershipAYTUAytu BioPharma4.90%HRTXHeron Therapeutics6.10%JATTJATT Acquisition20.00%RLYBRallybio10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAYTUAytu BioPharma16010.73 million10.21 millionNot OptionableHRTXHeron Therapeutics300189.28 million177.73 millionOptionableJATTJATT Acquisition38.03 million13.80 millionNot OptionableRLYBRallybio405.30 million4.75 millionNot OptionableAYTU, HRTX, JATT, and RLYB HeadlinesRecent News About These CompaniesRallybio (NASDAQ:RLYB) Shares Up 1% - What's Next?July 14, 2026 | americanbankingnews.comRallybio (NASDAQ:RLYB) Trading 1% Higher - Time to Buy?July 14, 2026 | marketbeat.comRallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYBJune 2, 2026 | businesswire.comRallybio, Avenzo agree oncology reverse merger backed by $215 million financingJune 2, 2026 | thepharmaletter.comTRLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own?June 1, 2026 | finance.yahoo.comRLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Price for its ShareholdersJune 1, 2026 | businesswire.comRallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private PlacementJune 1, 2026 | businesswire.comRallybio CorporationMay 22, 2026 | edition.cnn.comRallybio (NASDAQ:RLYB) Major Shareholder Adar1 Capital Management, Llc Buys 6,009 SharesMay 21, 2026 | insidertrades.comAdar1 Capital Management buys $1.11m of Rallybio (RLYB) stockMay 16, 2026 | investing.comInsider Buying: Rallybio (NASDAQ:RLYB) Major Shareholder Purchases 79,259 Shares of StockMay 16, 2026 | insidertrades.comRallybio (NASDAQ:RLYB) Major Shareholder Adar1 Capital Management, Llc Acquires 800 SharesMay 14, 2026 | insidertrades.comRallybio (NASDAQ:RLYB) Major Shareholder Adar1 Capital Management, Llc Purchases 35,101 SharesMay 7, 2026 | insidertrades.comRallybio Receives Termination Fee After Candid Deal CollapseMay 4, 2026 | tipranks.comRallybio CMO Departs Amid Pending Candid Therapeutics MergerMarch 31, 2026 | tipranks.comCandid lists via Rallybio reverse merger, adds $505m financingMarch 5, 2026 | thepharmaletter.comTRallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYBMarch 4, 2026 | businesswire.comRallybio Corp.March 3, 2026 | marketwatch.comRallybio Corporation and Candid Therapeutics Announce Merger AgreementMarch 2, 2026 | finance.yahoo.comRallybio Corporation (RLYB) M&A Call Prepared Remarks TranscriptMarch 2, 2026 | seekingalpha.comRallybio to Merge with Candid Therapeutics in All-Stock DealMarch 2, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAYTU, HRTX, JATT, and RLYB Company DescriptionsAytu BioPharma NASDAQ:AYTU$2.16 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$2.12 -0.04 (-2.08%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.Heron Therapeutics NASDAQ:HRTX$0.46 0.00 (-0.70%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$0.46 +0.00 (+0.04%) As of 07/24/2026 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.JATT Acquisition NYSE:JATT$11.31 +0.40 (+3.67%) Closing price 07/24/2026 03:54 PM EasternExtended Trading$11.24 -0.08 (-0.66%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.Rallybio NASDAQ:RLYB$16.31 -0.08 (-0.49%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$16.42 +0.11 (+0.67%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Plugging In: How Kinder Morgan Powers Up Profits TSMC’s Price Hikes Could Show Which AI Chip Stocks Have Real Pricing Power AMD’s $5 Billion Anthropic Deal Could Redraw the AI Chip Battle Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
